Regulatory Benefit-Risk Assessment and Comparative Effectiveness Research: Strangers, Bedfellows or Strange Bedfellows?

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.28, Iss.10, 2010-10, pp. : 855-865

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacoeconomics and Pharmacoepidemiology: Curious Bedfellows or a Match Made in Heaven?

By Briggs Andrew H.

PharmacoEconomics, Vol. 24, Iss. 11, 2006-01 ,pp. : 1079-1086

Adis International

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout: Was its Withdrawal from the Market in the Best Interest of Patients?

By Lee Ming-Han H. Graham Garry G. Williams Kenneth M. Day Richard O.

Drug Safety, Vol. 31, Iss. 8, 2008-01 ,pp. : 643-665

Adis International

Access to resources Recommend Favorite

Comparative effectiveness research: what future in the US?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 583, 2009-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Comparative Effectiveness Research and Personalized Medicine: Catalyzing or Colliding?

By Epstein Robert S. Teagarden J. Russell

PharmacoEconomics, Vol. 28, Iss. 10, 2010-10 ,pp. : 905-913

Adis International

Access to resources Recommend Favorite

Comparative Effectiveness Research: Improving Patient Care or Drug Rationing?

By Chou Roger

Drugs, Vol. 71, Iss. 4, 2011-03 ,pp. : 383-386

Adis International

Access to resources Recommend Favorite